Quentiax

Quick links to important sections

Quentiax

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quentiax

Quick Facts

Property Description
Active ingredient Quetiapine (as quetiapine fumarate)
Form Film-coated tablets (Immediate- or Prolonged-release)
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic, SGA)
Typical use Helping to stabilize thought and mood processes
Origin Synthetic, dibenzothiazepine derivative

1. Defining Quentiax: A Second-Generation Antipsychotic

Quentiax is a prescription-only psychotropic agent containing the active ingredient quetiapine, a synthetic compound utilized to help stabilize neurochemical balance in the brain. It is classified as an atypical antipsychotic (or Second-generation antipsychotic, SGA), a categorization characterized by its balanced effects on the central nervous system.

This classification is functionally important as it signifies a mechanism that modulates both dopamine and serotonin receptor systems, distinguishing it from older compounds that focused primarily on dopamine. This balanced action is recognized in clinical practice to support the stabilization of thought processes and the regulation of severe emotional states, which is its core general purpose.


2. Composition, Form, and Unique Features

The fundamental composition of Quentiax centers on the active ingredient quetiapine, typically present as the salt form, quetiapine fumarate. It is designed for oral administration as a single-component product formulated into film-coated tablets.

A key differentiating factor for the product is the availability of two distinct forms: immediate-release (IR) and specialized prolonged-release (SR or XR) tablets. The prolonged-release formulation is engineered to release the quetiapine steadily over an extended period. This distinction in delivery method is often utilized for conditions requiring consistent drug levels throughout the day.


3. How Quetiapine (Quentiax) Affects Brain Signaling

The general mechanism by which Quentiax functions involves its influence on brain communication, specifically by acting as a neurotransmitter receptor antagonist. The drug functions by adjusting the activity of key chemical messengers, primarily dopamine and serotonin, which are essential for stable mood and perception.

The parent compound’s metabolite, norquetiapine, also plays a significant role in the overall effect, contributing to its efficacy in mood stabilization. This dual compound action helps to stabilize signaling pathways in the central nervous system to promote mental clarity.

Regulatory References

  1. Quetiapine (Seroquel/Seroquel XR) - EMA Referral

What side effects are possible with Quentiax?

Possible side effects and safety information

Official regulatory documentation classifies the possible adverse reactions of Quentiax (quetiapine) based on frequency and affected body system. These classifications structure the understanding of the medicine's safety profile.

Frequency-Classified Adverse Reactions

Adverse reactions that are classified as Very Common (affecting 1 in 10 individuals or more) typically include somnolence (drowsiness), dizziness, dry mouth, weight gain, and withdrawal symptoms following abrupt cessation. Common reactions (affecting 1 in 100 individuals or more) often involve tachycardia, orthostatic hypotension (a drop in blood pressure upon standing), constipation, headache, and certain extrapyramidal symptoms.

Systemic Safety Patterns

The label-documented adverse events are grouped by System-Organ-Class. Notable categories include Metabolism and Nutrition Disorders (e.g., changes in blood glucose and lipid levels), Nervous System Disorders (e.g., seizures, tardive dyskinesia), and Cardiac and Vascular Disorders (e.g., orthostatic hypotension). Effects such as somnolence and dizziness are generally reported as being more common during the initial dose titration period.

Serious Adverse Reactions and Special Populations

Regulatory warnings highlight serious, though often rare, reactions, including Neuroleptic Malignant Syndrome (NMS) and the potential for Suicidal Thoughts and Behaviors, particularly in children, adolescents, and young adults. Specific safety considerations are noted for certain groups: official documents state an increased risk of stroke and mortality in older adults with dementia-related psychosis, and a higher risk of elevated blood pressure and metabolic changes in pediatric patients.

Overdose and Emergency Response

The official regulatory documentation for Quentiax (quetiapine) defines overdose by its primary effects on the central and cardiovascular systems.

Documented Overdose Manifestations

The clinical findings reported in human experience include severe somnolence (profound drowsiness), tachycardia (rapid heartbeat), and hypotension (low blood pressure).

Overdose carries the risk of severe, life-threatening outcomes, including Central Nervous System (CNS) depression that may progress to coma, respiratory depression requiring mechanical ventilation, and seizures. Documented cardiovascular risks include QT prolongation (a change in heart rhythm) and the ultimate risk of death.

When to Seek Urgent Help

Due to the potential for rapid deterioration and severe outcomes, regulatory authorities mandate that patients seek immediate medical attention and contact emergency services for any suspected overdose event.

Official Management and Monitoring

Overdose management is defined as symptomatic and supportive treatment, as the official labeling states that no specific antidote is known. Procedures such as gastric lavage and the administration of activated charcoal may be considered. Continuous cardiac monitoring (ECG) is specifically required to observe for arrhythmias and QT prolongation. The prolonged-release (XR) formulation may result in a delayed onset and prolonged duration of effects, necessitating extended observation periods.

Therapeutic Uses of Quentiax

What Quentiax Treats: Main Uses and Benefits

Quentiax (quetiapine) is commonly used to help with the symptomatic management of conditions such as Schizophrenia, Bipolar Disorder (including acute manic, mixed, and depressive episodes), and as an adjunctive therapy for Major Depressive Disorder (MDD). The medication plays a role in managing symptoms that interfere with daily functioning in situations involving acute or chronic symptom patterns.

The medication plays a role in addressing symptom clusters that may become intense or disruptive, especially those linked to psychosis or severe mood instability. It is relevant when supportive symptom management is appropriate, particularly in situations where patients experience heightened symptoms.

“It is applied across domains where additional symptomatic support is needed; it may help patients cope more steadily with symptom fluctuations.”

In clinical settings, Quentiax is often used during phases when symptoms become more noticeable, both for acute stabilization and for long-term maintenance treatment to manage the risk of symptom recurrence. This supportive relief contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Key Symptom Domains Description
Psychotic Symptoms Helps manage disturbances in thought and perception, such as delusions and hallucinations.
Manic Symptoms Applied to ease intense manifestations like elevated mood and overactivity during acute episodes.
Depressive Symptoms Provides symptomatic support for profound sadness and loss of interest in bipolar depression.

Eligibility and Restrictions for Use

Eligibility for Quentiax (Quetiapine): Official Regulatory Information

This section outlines who is and is not eligible to use Quentiax, based strictly on authoritative government regulatory documents.

Contraindications (Who Must Not Use Quentiax):

  • Hypersensitivity: Patients with a known allergy to quetiapine or any of the product’s ingredients.
  • Drug Interactions: Individuals taking strong CYP3A4 inhibitors (such as certain antifungals or HIV medications).
  • Elderly Patients: The medicine is explicitly contraindicated for treating psychosis related to dementia in older adults due to a documented increased risk of death (Black Box Warning).

Age and Physiological Restrictions:

Population Group Eligibility Status (Regulatory)
Pediatrics (<18 yrs) Not recommended for most uses; efficacy and safety are not established for children under 10.
Hepatic Impairment Restricted use; caution is required, and a lower starting dose (e.g., 25 mg/day) and slower titration are necessary.
Pregnancy/Lactation Restricted use; should only be used if the potential benefit justifies the potential risk. Breastfeeding is generally not recommended.

Individuals with cardiovascular disease, a history of seizures, or conditions predisposing to hypotension also require special caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Quentiax's official interaction profile is characterized by its high dependence on the Cytochrome P450 3A4 (CYP3A4) enzyme for metabolism, as documented in government regulatory labeling.

Pharmacokinetic Interactions (Drug Exposure)

  • Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors, such as Ketoconazole, Ritonavir, or Nefazodone, is contraindicated in some regions (SmPC) due to substantially decreased clearance and increased quetiapine exposure.
  • Potent CYP3A4 Inducers: Co-administration with potent inducers, including Phenytoin, Rifampin, and the herbal product St. John's wort, increases quetiapine clearance, leading to significantly reduced plasma concentrations.

Pharmacodynamic Interactions (Additive Effects)

  • CNS Depressants and Alcohol: Using quetiapine with other centrally acting agents or alcohol (ethanol) may lead to additive cognitive and motor effects and is generally advised against in official labeling.
  • Anticholinergic Agents: Co-administration with other anticholinergic drugs increases the potential for additive anticholinergic effects.
  • Antihypertensive Agents: The potential for additive hypotensive effects is documented when quetiapine is combined with antihypertensive agents.

Food and Substance Restrictions

  • Grapefruit/Grapefruit Juice: Consumption should be avoided as it inhibits the CYP3A4 enzyme, leading to increased quetiapine blood levels.
  • Extended-Release Formulation (XR): The prolonged-release tablet must be taken without food or with a light meal (approximately 300 calories) to maintain documented absorption and exposure characteristics. Taking the XR formulation with a large meal increases its plasma concentration.

Population-Specific Notes

  • Hepatic Impairment: Caution is noted for patients with known hepatic impairment due to the drug’s extensive reliance on hepatic metabolism for clearance, which affects the relevance of metabolic interactions.

The regulatory documentation classifies these interactions as highly clinically significant, guiding specific constraints on co-administration to manage substantial alterations in drug exposure or additive pharmacodynamic risks.

Mechanism of Action

Dual Action on Serotonin and Dopamine Systems

Quentiax's primary action is antagonism (blocking) at the central Serotonin 5-HT2A and Dopamine D2 receptors. This mechanism, defined by a high 5-HT2A/ D2 receptor binding ratio, adjusts activity within specific neural circuits, resulting in altered influence on the transmission of thought processes. Its transient engagement of the D2 receptor minimally affects the nigrostriatal pathway.


Mechanistic Enhancement via the Active Metabolite

The active metabolite, norquetiapine, provides a secondary mechanism by acting as a partial agonist at the 5-HT1A receptor and inhibiting the Norepinephrine Transporter (NET). This results in an increased synaptic concentration of norepinephrine and contributes to the modulation of monoamine pathways.


Off-Target Effects Driving Physiological Consequences

The drug exhibits affinity for the Histamine H1 and Alpha-1 (alpha1) adrenergic receptors. Central H1 antagonism suppresses alertness, which is linked to the physiological consequence of sedation. The alpha1 antagonism reduces peripheral vascular tone, resulting in orthostatic hypotension.

Dosage and Administration Information

Instruction Map: How to Use Quentiax — Administration Guidelines

Quentiax (quetiapine) is utilized for oral administration as a film-coated tablet, available in both Immediate-Release (IR) and Extended-Release (XR) formulations. The difference between these forms dictates the administration schedule and conditions.

Dosing and Schedule Instructions involve a gradual dose adjustment, known as titration. Treatment begins with a low initial dose (e.g., 25 mg or 50 mg) and is slowly increased over several days to reach an indication-specific maintenance range, typically 400 to 800 mg/day for major indications. The IR tablets are often taken twice or three times daily in divided doses, while the XR tablets are taken once daily, preferably in the evening.

Administration Conditions IR tablets may be taken with or without food. However, the XR tablets are taken without food or with a light meal only, and they must be swallowed whole without splitting, crushing, or chewing to preserve the prolonged-release action. For older adults and individuals with severe hepatic impairment, standard protocols involve initiating treatment at a lower starting dose and following a slower titration rate. If a dose is missed, it should be skipped, and the patient should continue with the regular schedule, avoiding a double dose. This protocol defines the precise use of the medicine.

Recent Clinical Evidence

Quentiax: Recent Clinical Evidence


Evidence for Use in Acute Schizophrenia and Preventing Recurrence

Research for Quentiax in schizophrenia has primarily focused on studying periods of heightened symptom activity using short-term Randomized Controlled Trials (RCTs). These studies examined how symptoms were measured and how they evolved in adult and adolescent populations, monitoring outcomes on standardized clinical rating scales over approximately six weeks. For preventing recurrence, evidence stems largely from randomized withdrawal designs observing patients over longer periods. These findings describe patterns observed in studies examining clinical stability over time. However, this structure means that evidence largely describes preventing recurrence in patients who previously responded, and limited direct information is available on long-term functional recovery.


Evidence for Stabilization in Bipolar Disorder

The evidence landscape for Quentiax in Bipolar Disorder is separated into trials that examined phases of heightened symptom activity (mania/mixed) and those that examined episodes of depression. Research for acute mania involved short-term RCTs, using the drug alone or in combination with other treatments, to monitor changes in manic symptom intensity. For bipolar depression, evidence was derived from intermediate-term RCTs conducted as monotherapy, exploring how depressive symptoms changed over approximately eight weeks. Certainty remains low regarding sustained, long-term effects on depressive episodes themselves, as the research primarily focuses on the acute treatment phase.

--punto de parada

Key Limitations and Areas of Uncertainty

The current body of research contributes to the broader evidence landscape but highlights areas where understanding is still evolving. Evidence quality varies across studies, and some trials exploring short-term symptom changes had modest sample sizes. Data indicate patterns related to symptom changes, but findings were mixed in some scenarios, and long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Quentiax (FAQ)


Q: How quickly does Quentiax start to work for its main purposes?

According to official information, starting treatment involves a gradual dose adjustment (titration). For managing acute symptoms, some response may be observed within the first week of treatment. However, the full intended therapeutic effect, especially for indications like bipolar depression, may not be achieved until four to six weeks.


Q: What is the typical timeframe before noticing a change with Quentiax?

Clinical trial data indicate that noticing the full benefit of Quentiax typically takes several weeks. As the dose is adjusted, changes may be gradual. Trial outcomes for full benefit in certain conditions are often monitored over six to eight weeks.


Q: Can Quentiax cause long-term changes to my metabolism or weight?

Regulatory documents indicate that changes to metabolic factors may occur with this medication. These documented effects include weight gain and changes in blood lipid and blood glucose levels. These effects are often associated with the duration of use.


Q: Is Quentiax safe to use if I am already taking herbal supplements?

Official product information describes the importance of the CYP3A4 liver enzyme in processing Quentiax. Regulatory documents note that some herbal supplements, such as St. John's wort, can interfere with this process, potentially decreasing the drug's concentration.


Q: What official guidance exists on discontinuing Quentiax?

Official label information warns against the abrupt cessation of Quentiax. Stopping the treatment suddenly may result in acute withdrawal symptoms. These documented symptoms can include difficulty sleeping (insomnia), nausea, vomiting, or restlessness.


Q: Does the regulatory information define any long-term effects of Quentiax use?

Regulatory documents describe Tardive Dyskinesia as a potential effect associated with long-term use. This condition is characterized by involuntary movements, most commonly affecting the face and tongue. Data indicates the risk may rise with the duration of treatment.


Q: How long after taking Quentiax should I wait before driving?

The official safety information warns that this medication may cause somnolence (drowsiness) and dizziness, which can impair a person's ability to drive or operate machinery, especially when first starting or after a dose increase.


Q: Is Quentiax considered a tranquilizer or a sleeping aid?

Quentiax is classified as an atypical antipsychotic. However, its chemical structure is documented to block the Histamine H1 receptor in the brain, an action associated with the commonly reported side effect of somnolence (drowsiness).


Q: Why is Quentiax sometimes prescribed for conditions other than psychosis?

Official documents state that Quentiax is approved for multiple uses beyond schizophrenia (a form of psychosis). It is also officially approved for treating episodes associated with bipolar disorder, including both manic and depressive episodes, and for maintenance treatment of bipolar disorder.


Q: Does taking Quentiax affect my ability to drive or operate heavy machinery?

Official safety information explicitly states that Quentiax may cause drowsiness and dizziness. These effects can impair a person's ability to perform tasks requiring mental alertness, such as driving or operating heavy machinery.


Q: Does Quentiax have a known risk of dependence or addiction?

Regulatory information notes that Quentiax is not designated as a controlled substance. However, regulatory documents include warnings that abrupt cessation may lead to physical withdrawal symptoms.


Q: Does Quentiax accumulate in the body over time?

Pharmacokinetic data from official documents describes that the drug typically reaches steady-state plasma concentrations within about two days of administration. Steady-state is the point where the amount of drug entering the body generally equals the amount leaving the body.


Q: Is it true that Quentiax is associated with a risk of cataracts?

Official regulatory documents describe the need for an ophthalmological examination (such as a check for cataracts) before starting treatment and at regular intervals during chronic treatment. This measure is recommended based on findings observed in animal studies.


Q: Why do some people feel restless or agitated after taking Quentiax?

Restlessness or agitation is a documented side effect known as akathisia. This is classified as one of the extrapyramidal symptoms (EPS) that may occur with this class of medication, according to the official adverse reaction profile.


Q: Can Quentiax affect the results of certain medical tests?

Official product information reports that the active ingredient in Quentiax has the potential to interfere with certain urine drug screening tests. This interference may potentially lead to false positive results for substances like methadone or tricyclic antidepressants.


Q: What research exists about Quentiax and its potential effect on memory?

The official label lists side effects that involve the central nervous system, such as somnolence, dizziness, and confusion, which may affect attention and concentration. However, the regulatory documentation does not specifically list long-term memory loss as a side effect.


Q: Are there different trade names for the drug Quentiax internationally?

The active ingredient, quetiapine, is sold under various trade names globally, depending on the country and manufacturer. Other common trade names documented in different regions include Seroquel.


Q: Is Quentiax known to cause excessive sweating?

Excessive sweating is listed in the regulatory adverse reaction profile. It is typically classified as an uncommon side effect.


Q: Is it normal to have vivid dreams or nightmares on Quentiax?

Official regulatory documents list nightmares or abnormal dreams in the adverse reaction profile. These effects are typically classified as an uncommon side effect.

How should Quentiax be stored and disposed of?

Storage and Disposal Requirements

Quentiax (quetiapine fumarate) must be stored under specific environmental and safety conditions as mandated by regulatory documents to maintain its stability.


Storage Conditions

The product must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be protected from light and kept in a dry place; the container should be tightly closed when not in use. A crucial safety requirement is to keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Quentiax should ideally be disposed of through a dedicated drug take-back program. If one is unavailable, the product must not be flushed down the toilet, as quetiapine is classified as potentially toxic to the aquatic environment. In this scenario, the drug can be mixed with an undesirable substance, sealed in a bag, and placed in the household trash, after removing all identifying information from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quentiax found in:

A-Z Index: